Bg pattern

INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes

Prescription review online

Prescription review online

A doctor will review your case and decide whether a prescription is medically appropriate.

Talk to a doctor about this medicine

Talk to a doctor about this medicine

Discuss your symptoms and possible next steps in a quick online consultation.

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.
About the medicine

How to use INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes

Translated with AI

This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.

Show original

Introduction

Package Leaflet: Information for the User

innohep 4,500 IU anti-Xa/0.45 ml solution for injection in pre-filled syringes

(10,000 IU anti-Xa)

tinzaparin sodium

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

  • Keep this leaflet, you may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist, or nurse.
  • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
  • If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in this leaflet.
  • In this leaflet, the term "innohep" refers to "innohep 4,500 IU anti-Xa/0.45 ml solution for injection in pre-filled syringes".

Contents of the pack

  1. What is innohep and what it is used for
  2. What you need to know before you use innohep
  3. How to use innohep
  4. Possible side effects
  5. Storage of innohep
  6. Contents of the pack and other information

1. What is innohep and what it is used for

innohep is a medicine that makes the blood more fluid by reducing the blood's natural ability to form clots.

innohep is used to

  • prevent the formation of blood clots in adults before and after surgery.
  • prevent the formation of blood clots in adults with a higher risk of blood clot formation, for example, due to an acute illness with limited mobility.

prevent the formation of blood clots in the blood in hemodialysis equipment in patients undergoing hemodialysis or hemofiltration. In hemodialysis, waste and fluids from the blood are removed by the machine and the dialysis filter that acts like an artificial kidney.

Doctor consultation

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

2. What you need to know before you use innohep

Do not use innohep:

  • if you are allergic to tinzaparin sodium or any of the other ingredients of this medicine (listed in section 6).
  • if you have or have had heparin-induced thrombocytopenia.
  • if you have a severe bleeding disorder (e.g., in the brain, spinal cord, eyes, or stomach).
  • if you have a severe infection of the heart (septic endocarditis).

Warnings and precautions

Consult your doctor or nurse before starting to use innohep:

  • if you are going to have a spinal or epidural anesthesia or a lumbar puncture.
  • if you know you have a tendency to bleed.
  • if you are being treated with other medicines by injection.
  • if you have a low platelet count in your blood.
  • if you have high levels of potassium in your blood (hyperkalemia).
  • if you have a prosthetic heart valve.
  • if you have kidney problems.

Children and adolescents

innohep is not indicated for use in children and adolescents.

Using innohep with other medicines

Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines. Some medicines may interact with the effect of innohep.

Tell your doctor if you are using any of the following medicines as you may bleed more easily:

  • Medicines for the treatment of inflammation and pain, especially non-steroidal anti-inflammatory drugs (NSAIDs), such as acetylsalicylic acid.
  • Medicines used to dissolve blood clots (thrombolytic agents)
  • Medicines that block the action of vitamin K (vitamin K antagonists)
  • Activated protein C
  • Direct inhibitors of factor Xa and IIa.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.

innohep in pre-filled syringes can be used during all trimesters of pregnancy.

If epidural anesthesia is necessary, you must inform your doctor that you are using innohep.

Tell your doctor or nurse if you have a prosthetic heart valve.

Driving and using machines

innohep does not affect the ability to drive and use machines.

innohep contains sodium

This medicine contains less than 23 mg of sodium (1mmol) per ml; this is essentially "sodium-free".

3. How to use innohep

Follow exactly the administration instructions of this medicine indicated by your doctor or nurse. If in doubt, consult your doctor or nurse again.

Your doctor may ask you to have routine blood tests to assess the effect of innohep.

To prevent the formation of blood clots in your veins

innohep must be injected under the skin (subcutaneous injection). The dose and duration of treatment will depend on the type of surgery or illness you have. Your doctor will indicate the appropriate dose for you and the duration of your treatment.

To prevent the formation of blood clots in the blood during hemodialysis or hemofiltration

innohep will be introduced into the circuits of the hemodialysis machine or administered intravenously. The dose will depend on the duration of dialysis.

Instructions on how to inject innohep:

  1. Wash your hands carefully before injecting this medicine. Clean the skin around the injection site with an alcohol swab and let it dry without rubbing.

Hands holding an injection device with exposed needle and arrow indicating direction of insertion

  1. Open the syringe container by lifting the colored cap all the way back and remove the syringe.

Inspect the contents of the syringe before use. If you notice turbidity or a precipitate in the medicine, do not use it and take another syringe. The medicine may have a yellowish color during storage, but it can be used as long as the solution is clear and the expiration date has not been exceeded. Each syringe can only be used once.

Hand holding a syringe with exposed needle while another hand guides the insertion into the skin

  1. Fold the safety device downwards, separating it from the needle protector cap.

Two hands holding a syringe with exposed needle preparing for a subcutaneous or intramuscular injection

  1. Remove the cap that protects the needle without twisting it. Do not pull the plunger back or remove the air bubble contained in the syringe. If the air bubble is not correctly positioned next to the plunger, gently tap the syringe until the air bubble is in place, next to the plunger.

Hand holding a syringe with needle inserted into the skin of the arm at an inclined angle showing the injection site

  1. Take a skin fold, without pressing, between the thumb and index finger of one hand and with the other hand insert the needle vertically into the skin fold, i.e., at a right angle to the skin.

Schematic representation of injection areas on the arms and legs with multiple marked points and indicative lines

  1. Slowly inject the necessary dose into the fatty tissue, for example, the skin of the abdominal area, the front of the thighs, the lower back, or the back of the arms. Wait a few seconds to allow the solution to spread before removing the needle and releasing the skin fold.
  1. Clean the area with a swab if you have bled. Choose a different injection site for the next time (e.g., alternating between the left and right side of the abdomen).

Hand holding a syringe with needle inserted into the skin showing a circular motion and downward pressure

Hand holding a pre-filled pen with needle being inserted into the skin with a rotational movement indicated by a curved arrow

  1. Fold the safety device back to its original position so that it is parallel to the needle. Then, with the safety device flat on a rigid surface, press down until the needle is locked in the device.

Hand holding an applicator device with needle inserted and arrow indicating direction of withdrawal

  1. The used syringe, with the needle facing down, can be inserted into the syringe container or a container for sharp objects. In this way, the syringe is safe, and the container with the syringe or the container for sharp objects can be delivered to a hospital or pharmacist for destruction.

If you use more innohep than you should

If you are treated with more innohep than you need, bleeding may occur. Consult your doctor or nurse immediately if you do not feel well or think you have been given too high a dose of innohep.

In case of overdose or accidental ingestion, you can also contact the Toxicology Information Service. Telephone 91 562 04 20.

If you forget to use innohep

Do not take a double dose to make up for forgotten doses. If you have forgotten to take more than one dose, consult your doctor as soon as possible.

If you stop using innohep

If you stop using innohep, the effect of making the blood more fluid will cease. Do not stop using innohep without consulting your doctor or nurse.

If you have any further questions on the use of this product, ask your doctor or nurse.

Medicine questions

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

4. Possible side effects

Like all medicines, innohep can cause side effects, although not everybody gets them.

Serious side effects:

Rarely, serious side effects are observed that require immediate medical attention during treatment with innohep. If you experience any of the following symptoms, consult your doctor immediately or go to the nearest hospital for emergency treatment.

  • Severe allergic reaction. Symptoms include sudden appearance of a severe skin rash, swelling of the throat, face, lips, or mouth, difficulty breathing.
  • Severe bleeding. Symptoms include urine that is red or brown, stools with a tar-like appearance, unusual bruising (very painful, extensive, or dark) and any bleeding that does not stop.

The following side effects have been observed with the administration of innohep:

Common: may affect up to 1 in 10 people

  • Bleeding. This can lead to complications such as anemia (a low number of red blood cells in the blood) or bruising.
  • Reactions at the injection site (including bruising, bleeding, pain, itching, redness, inflammation, and hardening of the injection site)

Uncommon: may affect up to 1 in 100 people

  • Thrombocytopenia (decrease in the number of platelets in the blood)
  • Hypersensitivity (allergic reaction)
  • Bruising and skin discoloration
  • Elevation of liver enzyme levels
  • Dermatitis (skin inflammation)
  • Rash and itching

Rare: may affect up to 1 in 1,000 people

  • Heparin-induced thrombocytopenia (decrease in the number of platelets in the blood due to heparin treatment)
  • Thrombocytosis (increase in the number of platelets in the blood)
  • Angioedema (swelling of the face, lips, and tongue)
  • Anaphylactic reaction (see above "Severe allergic reaction")
  • Hyperkalemia (elevated potassium levels in the blood)
  • Toxic skin rash
  • Necrosis of the skin
  • Hives
  • Osteoporosis, observed in long-term treatments
  • Priapism (prolonged, often painful, erection without previous sexual stimulation)

Pediatric population

Limited information is available, derived from a clinical trial and post-marketing data, indicating that the profile of adverse reactions in children and adolescents is comparable to that observed in adults.

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of innohep

  • Keep this medicine out of the sight and reach of children.
  • Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of the month shown.
  • No special storage conditions are required.
    • Do not use this medicine if you notice turbidity or a precipitate in the syringe.
    • The solution may have a yellowish color during storage, but this does not affect the quality of the product, which is still safe to use.
    • Medicines should not be disposed of via wastewater or household waste. Place the empty container and any unused medicine in the SIGRE container at the pharmacy. If in doubt, ask your pharmacist how to dispose of the container and any unused medicine. This will help protect the environment.

6. Contents of the pack and other information

Composition of innohep

  • The active substance is tinzaparin sodium. Each ml of solution for injection contains 10,000 IU anti-Xa of tinzaparin sodium.
    • The other ingredients are sodium acetate, sodium hydroxide, and water for injections.

Appearance and packaging

Solution for injection.

Transparent glass syringes containing a clear or pale yellow solution that does not show turbidity or sediment when the syringe is left to stand.

Pack sizes:

  • 0.45 ml (4,500 IU anti-Xa), packs of 2, 10, and 50 syringes.

Not all pack sizes may be marketed.

Marketing Authorisation Holder

LEO Pharma A/S

Industriparken 55

DK-2750 Ballerup

Denmark

Manufacturer

Laboratoires LEO S.A.

39 Route de Chartres

FR-28500 Vernouillet Cedex

France

Date of last revision of this leaflet: December 2019

Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.

Online doctors for INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes

Discuss questions about INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0 (69)
Doctor

Tarek Agami

General medicine 11 years exp.

Dr. Tarek Agami is a general practitioner registered in both Portugal and Israel, with broad experience in family and preventive medicine. He offers online consultations for adults and children, providing personalised support for primary care needs, chronic disease management, and everyday health concerns.

Dr. Agami received clinical training and worked in leading medical institutions in Israel (Kaplan Medical Center, Barzilai Medical Center, Wolfson Medical Center) and Portugal (European Healthcare City, Viscura Internacional, Hospital Dr. José Maria Grande, Hospital Vila Franca de Xira). His approach combines international medical standards with individualised attention to each patient.

Main areas of consultation:

  • Diagnosis and treatment of acute and chronic conditions (high blood pressure, diabetes, respiratory infections, cardiovascular symptoms)
  • Evaluation of symptoms and guidance on further diagnostic testing
  • Preventive check-ups and regular health monitoring
  • Medical support during travel or after relocation
  • Treatment adjustments and lifestyle recommendations based on your personal history
Dr. Agami provides medical support for patients using GLP-1 medications (such as Ozempic or Mounjaro) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Portugal and Israel.

Dr. Agami is committed to evidence-based, patient-centred care, ensuring that each person receives trusted medical support tailored to their health goals.

Camera Book a video appointment
€69
5.0 (63)
Doctor

Nuno Tavares Lopes

Family medicine 18 years exp.

Dr. Nuno Tavares Lopes is a licensed physician in Portugal with 17 years of experience in emergency medicine, family and general practice, and public health. He is the Director of Medical and Public Health Services at an international healthcare network and serves as an external consultant for the WHO and ECDC.

  • Emergency care: infections, fever, chest/abdominal pain, minor injuries, paediatric emergencies
  • Family medicine: hypertension, diabetes, cholesterol, chronic disease management
  • Travel medicine: pre-travel advice, vaccinations, fit-to-fly certificates, travel-related illnesses
  • Sexual and reproductive health: PrEP, STD prevention, counselling, treatment
  • Weight management and wellness: personalised weight loss programmes, lifestyle guidance
  • Skin and ENT issues: acne, eczema, allergies, rashes, sore throat, sinusitis
  • Pain management: acute and chronic pain, post-surgical care
  • Public health: prevention, health screenings, long-term monitoring
  • Sick leave (Baixa médica) connected to Segurança Social in Portugal
  • IMT medical certificates for driving licence exchange
Dr. Nuno Tavares Lopes provides medical support for patients using GLP-1 medications (Mounjaro, Wegovy, Ozempic, Rybelsus) as part of a weight loss strategy. He offers individualised treatment planning, regular follow-up, dose adjustment, and advice on combining medication with sustainable lifestyle changes. Consultations follow the medical standards accepted in Europe.

Dr. Lopes also provides interpretation of medical tests, follow-up care for complex patients, and multilingual support. Whether for urgent concerns or long-term care, he helps patients act with clarity and confidence.

Camera Book a video appointment
€59
5.0 (3)
Doctor

Tomasz Grzelewski

Dermatology 21 years exp.

Dr Tomasz Grzelewski is an MD, PhD specialist in allergy, paediatrics, general practice and sports medicine, with a clinical focus on dermatology, endocrinology, allergology and sports-related health. He has more than 20 years of clinical experience and completed his medical training at the Medical University of Łódź, where he defended his PhD thesis with distinction. His doctoral research was recognised by the Polish Society of Allergology for its innovative contribution to the field. Throughout his career, he has gained extensive expertise in diagnosing and managing a wide range of allergic and paediatric conditions, including modern allergen desensitisation techniques.

For five years, Dr Grzelewski served as the Head of two paediatric departments in Poland, managing complex clinical cases and leading multidisciplinary teams. He also worked in medical centres in the United Kingdom, gaining experience across both primary care and specialist environments. With over a decade of telemedicine experience, he has provided online consultations across Europe and is valued for his clear, structured and evidence-based medical guidance.

Dr Grzelewski is actively involved in clinical programmes focused on modern anti-allergic therapies. As a Principal Investigator, he leads research projects on sublingual and oral allergen desensitisation, supporting evidence-based progress in allergy treatment for both children and adults.

In addition to his background in allergology and paediatrics, he completed dermatology studies through the Cambridge Education Group (Royal College of Physicians of Ireland) and a Clinical Endocrinology course at Harvard Medical School. This advanced training enhances his ability to manage skin manifestations of allergies, atopic conditions, urticaria, endocrine-related symptoms and complex immunological reactions.

Patients commonly seek his care for:

  • seasonal and perennial allergies
  • allergic rhinitis and chronic nasal symptoms
  • asthma and breathing difficulties
  • food and medication allergies
  • urticaria, atopic dermatitis and skin reactions
  • recurrent infections in children
  • sports-related health questions
  • general family medicine concerns
Dr Tomasz Grzelewski is known for his clear communication style, structured medical approach and ability to explain treatment options in a concise and accessible way. His multidisciplinary background across allergy, paediatrics, dermatology and endocrinology allows him to provide safe, up-to-date and comprehensive care for patients of all ages.
Camera Book a video appointment
€80

Frequently Asked Questions

Is a prescription required for INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes?
INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes?
The active ingredient in INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes is tinzaparin. This information helps identify medicines with the same composition but different brand names.
How much does INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes cost in pharmacies?
The average pharmacy price for INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes is around 51.16 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes?
INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes is manufactured by Leo Pharma A/S. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
What are the alternatives to INNOHEP 4,500 IU Anti-Xa/0.45 mL Injectable Solution in Syringes?
Other medicines with the same active substance (tinzaparin) include INNOHEP 10,000 IU Anti-Xa / 0.5 ml Pre-filled Syringe Solution for Injection, INNOHEP 12,000 IU Anti-Xa/0.6 mL Pre-filled Syringe Solution for Injection, INNOHEP 14,000 IU Anti-Xa / 0.7 mL Pre-filled Syringe Solution for Injection. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
bg-pattern-dark

Stay informed about Oladoctor

News about new services, product updates and useful information for patients.

Follow us on social media